Fig 4.

(A) Progression-free survival (PFS) of patients treated with genomically matched therapy (n = 22) or nonmatched therapy (n = 54). All patients with follow-up who were treated with genomically matched therapy are included in the analysis, including one patient who was treated with off-label trametinib for a KRAS mutation when the board had recommended a clinical trial. (B) PFS and PFS on immediate prior therapy for individual patients treated with genomically matched therapies. Eight patients either had no prior systemic therapy for metastatic disease or insufficient documentation of prior therapy. Arrowheads indicate patients continuing on treatment. amp, amplification; CR, complete response; ER, estrogen receptor; PR, partial response; SD, stable disease; TNBC, triple-negative breast cancer.